Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

MAKO's Performance Still Pretty 'Meh'

Prior to its presentation at the annual JPMorgan Healthcare conference, MAKO Surgical (NASDAQ:MAKO) released some limited information about its fourth-quarter results. While MAKO avoided the big miss that some investors had feared, and system placement performance was in line with expectations, utilization continues to be a meaningful concern for this company.

Q4 Data - Placements Okay, Procedures Less So

For the fourth quarter of 2012, MAKO Surgical reported that it had sold 15 RIO systems around the world, basically matching Wall Street expectations. While two of the sales were overseas and appear to have a meaningful deferred revenue recognition treatment, that's a quibble at this point. It's worth noting, though, that while this performance matched expectations, the full-year...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details